Home › Trials › NCT07215559

Macupatide and eloralintide, alone or together, for weight loss in adults with type 2 diabetes

A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes

Phase 2 Interventional Eli Lilly and Company · NCT07215559

This trial tests whether the drugs macupatide and eloralintide, alone or combined, help adults with overweight or obesity and type 2 diabetes lose weight over about 48 weeks.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment200 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorEli Lilly and Company Industry-sponsored
Locations38 sites (Gilbert, Arizona and 37 other locations)
Trial IDNCT07215559 on ClinicalTrials.gov

What this trial studies

In this Phase 2 interventional trial adults with overweight or obesity and type 2 diabetes will receive macupatide, eloralintide, the two drugs in combination, or matched placebos for roughly 48 weeks. Study visits will monitor body weight, HbA1c, and safety measures while participants continue standard care (diet/exercise or stable metformin/SGLT2 therapy). The goal is to measure how much weight is lost and to track effects on blood sugar and adverse events. The design uses active and placebo injections to compare single-agent and combination effects on metabolic outcomes.

Who should consider this trial

Good fit: Ideal candidates are adults with type 2 diabetes (HbA1c 7.5–10.5%), a BMI ≥27, a stable weight for the prior 3 months, and on diet/exercise alone or a stable dose of metformin or an SGLT2 inhibitor.

Not a fit: Patients with other forms of diabetes, recent major cardiovascular events, recent or planned obesity surgery, active or recently treated malignancy, or who fall outside the HbA1c/BMI ranges are unlikely to qualify or benefit from this study.

Why it matters

Potential benefit: If successful, this approach could produce greater weight loss and improved blood sugar control for adults with overweight or obesity and type 2 diabetes.

How similar studies have performed: Other programs targeting incretin pathways (for example GLP-1/GIP agents) and amylin analogs have produced meaningful weight loss, but combining a GIP-directed agent like macupatide with an amylin analogue such as eloralintide is a newer strategy being tested in humans.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Have type 2 diabetes
* Have an HbA1c ≥7.5% to ≤10.5% at screening
* Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening

  * Diet and exercise
  * Stable dose of metformin
  * Sodium-glucose cotransporter-2 (SGLT2) inhibitor
* Have had a stable body weight (\<5% body weight gain and/or loss) for the 3 months prior to screening
* Have a BMI of 27 or greater at screening

Exclusion Criteria:

* Have any form of diabetes other than type 2 diabetes
* Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening
* Have any of the following cardiovascular conditions within 3 months prior to screening:

  * acute myocardial infarction
  * cerebrovascular accident (stroke)
  * unstable angina, or
  * hospitalization due to congestive heart failure
* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include

  * basal or squamous cell skin cancer
  * in situ carcinomas of the cervix, or
  * in situ prostate cancer
* Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:

  * amylin RA
  * dual amylin and calcitonin RA
  * glucagon-like peptide-1 receptor (GLP-1) RA
  * glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA
  * GLP-1/glucagon (GCG) RAs, or
  * GIP/GLP-1/GCG RAs
* Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides
* Have used insulin for diabetic control within the prior year (short term use in certain situations allowed

Where this trial is running

Gilbert, Arizona and 37 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions ObesityOverweightDiabetes Mellitus, Type 2GIPAmylin
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.